MINNEAPOLIS (PRWEB) September 21, 2006
The market for rheumatoid arthritis therapeutics has experienced remarkably strong growth during the past five years due to the introduction of the biological response modifiers (BRMs) to treatment regimens. Total sales of these products are expected to reach approximately $10 billion in 2006, according to a new report from Arrowhead Publishers entitled Rheumatoid Arthritis: Market Trends and R&D Insights. Sales of both Remicade and Enbrel continue to grow, while the introduction of Humira in 2003 has been a major stimulus to the market. All three of these products are now approved in both the US and Europe for rheumatoid arthritis. Added to this mix in 2006 was Rituxan and Orencia, which will also have an impact on this market. As half-year 2006 revenues clearly indicate, revenues from the sales of all of these products will continue to trend positively throughout the next five years.
Between 2006 and 2011, the value of the biologic market for the treatment of RA will grow by a CAGR of around 11 percent. Fueling growth in this market will be a general increase in the uptake of biologics for the treatment of rheumatoid arthritis as they gain greater acceptance from physicians. This class has demonstrated clinical superiority over traditional disease-modifying anti-rheumatic drugs (DMARDs) since the first approvals in 1998, which will continue to stimulate their revenue streams over the coming years. Higher level of patient disease education will also contribute to the trend, as will the aging of the American and European populations.
The rheumatoid arthritis pipeline today is replete with biologic therapies designed to modify the course of the disease. There are a number of follow-on biologic products being developed, which, like Remicade, Enbrel and Humira, target TNF-α. Additionally, though, companies are investing in candidates which target other cytokines that have been implicated in disease development. The success of the anti-TNF therapies has prompted further development in this area. Companies such as Centocor/Schering-Plough and Celltech/UCB are aiming to commercialize their own anti-TNF therapies which may prove competitive with currently marketed products if they can indeed offer better toxicity profiles and/or dosing regimens. Both biologics have reached Phase III and have demonstrated strong efficacy thus far.
There are few factors expected to slow down growth in this market during the next five years. Manufacturing capacity has been an issue in the past (eg. Enbrel), and could become problematic once more, but with big pharma backing the biologics in increasing numbers, Arrowhead anticipates few problems in this area.
Rheumatoid Arthritis: Market Trends and R&D Insights is now available from Arrowhead Publishers. For more information about this report or to request sample pages, contact us by email or call +1 612-929-5203.